Skip to main content
SpringerLink
Log in
Book cover

Therapieresistenz unter Neuroleptikabehandlung pp 13–23Cite as

Die prädiktorische Bedeutung einer Neuroleptika-Testdosis

  • Conference paper

Zusammenfassung

Vor dem Hintergrund nur begrenzter Vorhersagemöglichkeiten des Therapieansprechens mit Hilfe demographischer, anamnestischer und klinischer Variablen (Klorman et al. 1977, May und Goldberg 1978, Gelder und Kolakowska 1979, Woggon und Baumann 1982) stellt das sog. „Testdosismodell“ ein Verfahren zur Optimierung der Responsevorhersage dar (May et al. 1976, May und Goldberg 1978). Bei diesem Ansatz wird anhand klinischer, pharmakokinetischer, neuroendokrinologischer und psychophysiologischer Parameter die Reaktion des Organismus auf die Einzeldosis eines Pharmakons („Testdosis“) oder eine kurzfristige „Probebehandlung“ (Woggon und Baumann 1982) getestet. Aus der initialen Verlaufscharakteristik einzelner Parameter im Sinne einer „Akutresponse“, d.h. aufgrund der Dynamik interventionsbezogener Parameter (Helmchen 1983) wird der weitere Behandlungsverlauf prädiziert.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Alpert M, Diamond F, Weisenfreund J, Taleporos E, Friedhoff AJ (1978) The neuroleptic hypothesis: Study of the covariation of extrapyramidal and therapeutic drug effects. Br J Psychiatry 133: 169–175

    Google Scholar 

  • Awad AG, Hogan TP (1985) Early treatment events and prediction of response to neuroleptics in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 9: 585–588

    Article  PubMed  CAS  Google Scholar 

  • Bartko G, Herczeg I, Bekesy M (1987) Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement. J Clin Psychiatry 48: 363–365

    PubMed  CAS  Google Scholar 

  • Bente D (1963) Elektroenzephalographie und psychiatrische Pharmakotherapie. In: Achelis JD, v Ditfurth H (Hrsg) Anthropologische und naturwissenschaftlich-klinische Grundlagenprobleme der Pharmakopsychiatrie. Thieme, Stuttgart, S 75–99

    Google Scholar 

  • Böker W, Brenner HD, Alberti L (1983) Über eine Untersuchung subjektiver Neuroleptikawirkung bei Schizophrenen. In: Haase HJ (Hrsg) Psychopharmakotherapie. Perimed, Erlangen 1982

    Google Scholar 

  • Brown WA (1983) Prolactin levels and effects of neuroleptics. Psychosomatics 24 (6)

    Google Scholar 

  • Casper R, Garver DL, Dekirmenjian H, Chang S, Davis JM (1980) Phenothiazine levels in plasma and red blood cells. Arch Gen Psychiatry 37: 301–305

    Article  PubMed  CAS  Google Scholar 

  • Cohen BM, Lipinksi JF, Pope HG, Harris PQ, Altesman RI (1980) Neuroleptic blood levels and therapeutic effect. Psychopharmacology (Berl) 70: 191–193

    Article  CAS  Google Scholar 

  • Cooper TB, Simpson GM (1976) Plasma/blood level monitoring techniques in psychiatry. In: Gottschalk LA, Merlis S (eds) Pharmacokinetics of psychoactive drugs: Blood levels and clinical response. Spectrum, New York, pp 23–31

    Google Scholar 

  • Davila R, Manero E, Zumarraga M, Andia I, Schweitzer JW, Friedhoff AJ (1988) Plasma homovanillic acid as a predictor of response to neuroleptics. Arch Gen Psychiatry 45: 564–567

    Article  PubMed  CAS  Google Scholar 

  • Davis JM, Janowsky DS, Sekerke HJ, Manier H, El-Yousef MK (1974) The pharmacokinetics of butaperazine in serum. In: Forrest IS, Carr CJ, Usdin E (eds) Phenothiazines and structurally related drugs. Raven, New York

    Google Scholar 

  • Davis JM (1978) Dopamine theory of schizophrenia: a two-factor theory. In: Wynne LC, Cromwell RL, Matthysse S (eds) The nature of schizophrenia. Wiley, New York

    Google Scholar 

  • Davis HM, Erickson S, Dekirmenjian H (1978) Plasma levels of antipsychotic drugs and clinical response. In: Lipton MA, Dimascio A, Killam KF (eds) Psychopharmacology: A generation of progress. Raven, New York

    Google Scholar 

  • Farde L, Wiesel FA, Halldin C, Sedvall G (1988) Central D2-Dopmine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45: 71–76

    Article  PubMed  CAS  Google Scholar 

  • Filip V (1986) Clinical and pharmacokinetic prognosis of treatment efficacy in schizophrenia results of a multicenter study. IntJ Neurosci 31: 21

    Google Scholar 

  • Fink EB, Braden W, Quails CB (1982) Predicting pharmacotherapy outcome by subjective response. J Clin Psychiatry 43: 272–275

    PubMed  CAS  Google Scholar 

  • Frith CD, Stevens M, Johnstone EC, Crow TJ (1979) Skin conductance responsivity during acute episodes of schizophrenia as a predictor of symptomatic improvement. Psychol Med 9: 101–106

    Article  PubMed  CAS  Google Scholar 

  • Gaebel W, Pietzcker A (1987) Prospective study of course of illness in schizophrenia: Part II. Prediction of outcome. Schizophrenia Bull 13: 299–308

    Google Scholar 

  • Gaebel W, Pietzcker A, Ulrich G, Schley J, Müller-Oerlinghausen B (1988) Möglichkeiten der Voraussage des Erfolges einer Akutbehandlung mit Perazin anhand der Reaktion auf eine Perazintestdosis. In: Helmchen H, Hippius H, Tölle R (Hrsg) Therapie mit Neuroleptika — Perazin. Thieme, Stuttgart

    Google Scholar 

  • Gaebel W (1989) Indikatoren und Prädiktoren schizophrener Krankheitsstadien und Verlaufsausgänge. Habilitationsschrift, Freie Universität Berlin

    Google Scholar 

  • Gelder M, Kolakowska T (1979) Variability of response to neuroleptics in schizophrenia: Clinical, pharmacological, and neuroendocrine correlates. Compr Psychiatry 20: 397–408

    Google Scholar 

  • Gottschalk LA, Biener R, Noble EP, Birch H, Wilbert DE, Heiser JF (1975) Thioridazine plasma levels and clinical response. Compr Psychiatry 16: 323–337

    Article  PubMed  CAS  Google Scholar 

  • Gottschalk LA, Dinovo E, Biener R, Birch H, Syben M, Noble EP (1976) Plasma levels of mesoridazine and its metabolites and clinical response in acute schizophrenia after a single intramuscular drug dose. In: Gottschalk LA, Merlis S (eds) Pharmacokinetics of psychoactive drugs: Blood levels and clinical response. Spectrum, New York, pp 171–189

    Google Scholar 

  • Gruen PH, Sachar EJ, Altman N, Langer G, Tabrizi MA, Halpern FS (1978) Relation of plasma prolactin to clinical response in schizophrenic patients. Arch Gen Psychiatry 35: 1222–1227

    Article  PubMed  CAS  Google Scholar 

  • Haase HJ (1982) Die Dosierung der Neuroleptika unter feinmotorischer Kontrolle als konstruktiver Beitrag zum Thema der “Pharmakeule”. In: Haase HJ (Hrsg) Psychopharmakotherapie. Perimed, Erlangen

    Google Scholar 

  • Hansen LB, Larsen NE (1985) Therapeutic advantages of monitoring plasma concentrations of pherphenazine in clinical practice. Psychopharmacology (Berl) 87: 16–18

    Article  CAS  Google Scholar 

  • Helmchen H, Künkel H (1964) Der Einfluß von EEG-Verlaufsuntersuchungen unter psychiatrischer Pharmakotherapie auf die Prognostik von Psychosen. Arch Psychiat Zeitschr Ges Neurol 205: 1–18

    CAS  Google Scholar 

  • Helmchen H (1974) Significance of psychotropic drug-induced abnormal EEGs. Mod Probl Pharmacopsychiatry 8: 317–326

    Google Scholar 

  • Helmchen H (1983) Prediction of course and therapeutic response in psychiatric diseases. Pharmacopsychiatry 16: 173–174

    Article  CAS  Google Scholar 

  • Klorman R, Strauss JS, Kokes RF (1977) Premorbid adjustment in schizophrenia. Part IV. Some biological approaches to research on premorbid functioning in schizophrenia. Schizophr Bull 3: 226–239

    Google Scholar 

  • Kolakowska T, Orr M, Gelder M, Heggie M, Wiles D, Franklin M (1979) Clinical significance of plasma drug and prolactin levels during acute chlorpromazine treatment: A replication study. Br J Psychiatry 135: 352–359

    Google Scholar 

  • Kolakowska T, Gelder MG, Orr MW (1980) Drug-related and illness-related factors in the outcome of chlorpromazine treatment: Testing a model. Psychol Med 10: 335–343

    Google Scholar 

  • Magliozzi JR, Hollister LE, Arnold KV, Earle GM (1981) Relationship of serum haloperidol levels to clinical response in schizophrenic patients. Am J Psychiatry 138: 365–368

    PubMed  CAS  Google Scholar 

  • Marder SR, Hawes EM, Vanputten T, Hubbard JW, McKay G, Mintz J, May PRA, Midha KK (1986) Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate. Psychopharmacology (Berl) 88: 480–483

    Article  CAS  Google Scholar 

  • May PRA, Tuma AH, Yale C, Potepan P, Dixon WJ (1976a) Schizophrenia — a follow-up study of results of treatments. II. Hospital stay over two to five years. Arch Gen Psychiatry 33: 481–506

    Google Scholar 

  • May PRA, van Putten T, Yale C, Potepan P, Jenden DJ, Fairchild MD, Goldstein MJ, Dixon WJ (1976) Predicting individual responses to drug treatment in schizophrenia: A test dose model. J Nerv Ment Dis 162: 177–183

    Google Scholar 

  • May PRA, van Putten T (1978) Plasma levels of chlorpromazine in schizophrenia. Arch Gen Psychiatry 35: 1081–1087

    Article  PubMed  CAS  Google Scholar 

  • May PRA, van Putten T, Yale C (1980) Predicting outcome of antipsychotic drug treatment from early response. Am J Psychiatry 137: 1088–1089

    PubMed  CAS  Google Scholar 

  • May PRA, van Putten T, Jenden DJ, Yale C, Dixon WJ, Goldstein MJ (1981) Prognosis in schizophrenia: Individual differences in psychological response to a test dose of antipsychotic drug and their relationship to blood and saliva levels and treatment outcome. Compr Psychiatry 22: 147–152

    Google Scholar 

  • May PRA, van Putten T, Jenden DJ, Yale C, Dixon MJ (1981a) Chlorpromazine levels and the outcome of treatment in schizophrenic patients. Arch Gen Psychiatry 38: 202–207

    Article  PubMed  CAS  Google Scholar 

  • May PRA, Itil T, van Putten T, Lee MA, Yale C (1982) A preliminary attempt to relate individual differences in EEG test dose response to clinical effect. Biol Psychiat 17: 599–603

    PubMed  CAS  Google Scholar 

  • May PRA, Goldberg SC (1978) Prediction of schizophrenic patients’ response to pharmacotherapy. In: Lipton MA, Dimascio A, Killam KF (eds) Psychopharmacology: A generation of progress. Raven, New York, pp 113–1153

    Google Scholar 

  • McEvoy JP (1986) The neuroleptic threshold as a marker of minimum effective neuroleptic dose. Comp Psychiatry 27: 327–335

    Article  CAS  Google Scholar 

  • Meitzer HY, Stahl SM (1976) The dopamine hypothesis of schizophrenia. Schizophr Bull 2: 19–76

    Google Scholar 

  • Meitzer HY, Fang VS (1976) The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 33: 279–286

    Article  Google Scholar 

  • Meitzer HY, Busch DA, Fang VS (1983) Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res 9: 271–283

    Article  Google Scholar 

  • Meltzer HY, Busch D (1983) Serum prolactin response to chlorpromazine and psychopathology in schizophrenics: Implications for the dopamine hypothesis. Psychiatry Res 9: 285–299

    Google Scholar 

  • Midha KK (1985) Plasma levels as bioavailability measurements in neuroleptics. Integr Psychiatry 3: 71S–78S

    Google Scholar 

  • Möller HJ, Kissling W, Zerssen von D (1983) Die prognostische Bedeutung aes frühen Ansprechens schizophrener Patienten auf Neuroleptika für den weiteren stationären Behandlungsverlauf. Pharmacopsychiatry 16: 46–49

    Article  Google Scholar 

  • Möller HJ, Scharl W, Zerssen von D (1984) Störungen der prämorbiden sozialen Adaptation als Prädiktor für die Fünfjahresprognose schizophrener Psychosen. Nervenarzt 55: 358–364

    PubMed  Google Scholar 

  • Nahunek K, Ceskova E, Svestka J, Rysanek R, Misurec J (1985) Early predictors of the therapeutic outcome for clozapine in schizophrenia. Activ Nerv (Praha) [Suppl] 27: 55–56

    Google Scholar 

  • Nedopil N, Rüther E (1981) Initial improvement as predictor of outcome of neuroleptic treatment. Pharmacopsychiatry 14: 205–207

    Article  CAS  Google Scholar 

  • Rao VAR, Bishop M, Coppen A (1980) Clinical state, plasma levels of haloperidol and prolactin: A correlation study in chronic schizophrenia. Br J Psychiatry 137: 518–521

    Google Scholar 

  • Rivera-Calimlim L, Gift T, Nasrallah HA, Wyatt RJ, Lasagna L (1978) Correlation between plasma concentrations of chlorpromazine and clinical response. Community Psychopharmacol 2: 215–222

    CAS  Google Scholar 

  • Sakurai Y, Nakahara T, Takahashi R (1975) Prediction of response to chlorpromazine treatment in schizophrenics. Psychopharmacologia (Berl) 44: 195–203

    Article  CAS  Google Scholar 

  • Sakurai Y, Takahashi R, Nakahara T, Ikenaga H (1980) Prediction of response to and actual outcome of chlorpromazine treatment in schizophrenic patients. Arch Gen Psychiatry 37: 1057–1061

    Article  PubMed  CAS  Google Scholar 

  • Sedvall G, Farde L, Persson A, Wiesel FA (1986) Imaging of neurotransmitter receptors in the living human brain. Arch Gen Psychiatry 43: 995–1005

    Article  PubMed  CAS  Google Scholar 

  • Selbach C, Selbach H (1956) Phenothiazinwirkung und somatopsychische Dynamik. Nervenarzt 27: 145–149

    PubMed  CAS  Google Scholar 

  • Selbach H (1961) Über die vegetative Dynamik in der psychiatrischen Pharmakotherapie. Dtsch Med J 16: 511–517

    Google Scholar 

  • Simpson GM, Yadalam K (1985) Blood levels of neuroleptics: State of the art. J Clin Psychiatry 46: 22–28

    Google Scholar 

  • Singh MM, Kay SR (1979) Dysphoric response to neuroleptic treatment in schizophrenia: Its relationship to autonomic arousal and prognosis. Biol Psychiatry 14: 277–294

    Google Scholar 

  • Straube ER, Schied HW, Rein W, Breyer-Pfaff U (1987) Autonomic nervous system differences as predictors of short-term outcome in schizophrenics. Pharmacopsychiatry 20: 105–110

    Article  PubMed  CAS  Google Scholar 

  • Swigar ME, Jatlow PI, Goicpoechea N, Obsahl C, Bowers MB (1984) Ratio of serum prolactin to haloperidol and early clinical outcome in acute psychosis. Am J Psychiatry 141: 1281–1283

    PubMed  CAS  Google Scholar 

  • van Putten T, May PRA (1978) Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 35: 477–480

    Article  PubMed  Google Scholar 

  • van Putten T, May PRA, Jenden DJ, Cho AK, Yale C (1980) Plasma and saliva levels of chlorpromazine and subjective response. Am J Psychiatry 137: 1241–1242

    PubMed  Google Scholar 

  • van Putten T, May PRA, Jenden DJ (1981) Does a plasma level of chlorpromazine help? Psychol Med 11: 729–734

    Article  PubMed  Google Scholar 

  • van Putten T, May PRA, Marder SR, Wittmann LA (1981a) Subjective response to antipsychotic drugs. Arch Gen Psychiatry 38: 187–190

    Article  PubMed  Google Scholar 

  • van Putten T, May PRA, Marder SR (1984) Response to antipsychotic medication: The doctor’s and the consumer’s view. Am J Psychiatry 141: 16–19

    Google Scholar 

  • van Putten T, Marder SR (1986) Low-dose treatment strategies. J Clin Psychiatry 47: 12–15

    PubMed  Google Scholar 

  • van Putten T, Marder SR, Wirshing WC, Aravagiri M, Chabert N (1991) Neuroleptic plasma levels. Schizophrenia Bull 17: 197–216

    Google Scholar 

  • Wode-Helgodt B, Borg S, Fyrö B, Sedvall G (1978) Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatry Scand. 58: 149–173

    Article  CAS  Google Scholar 

  • Woggon B, Baumann U (1982) Voraussagbarkeit des Therapieerfolges bei der Behandlung mit Antidepressiva und Neuroleptika. Arzneimittelforschung 32: 868–869

    Google Scholar 

  • Woggon B, Baumann U (1983) Multimethodological approach in psychiatric predictor research. Pharmacopsychiatry 16: 175–178

    Article  CAS  Google Scholar 

  • Zahn TP, Carpenter WT, McGlashan TH (1981) Autonomic nervous sytem activity in acute schizophrenia. Arch Gen Psychiatry 38: 260–266

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Psychiatrische Klinik, Heinrich-Heine-Universität, Rheinische Landes- und Hochschulklinik Düsseldorf, Bergische Landstraße 2, D-40605, Düsseldorf, Bundesrepublik Deutschland

    Prof. Dr. W. Gaebel

Authors
  1. Prof. Dr. W. Gaebel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrischen Universitätsklinik und Poliklinik, Sigmund-Freud-Straße 25, D-53115, Bonn-Venusberg, Deutschland

    Hans-Jürgen Möller (Direktor) (Direktor)

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag/Wien

About this paper

Cite this paper

Gaebel, W. (1993). Die prädiktorische Bedeutung einer Neuroleptika-Testdosis. In: Möller, HJ. (eds) Therapieresistenz unter Neuroleptikabehandlung. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9292-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-9292-4_2

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-82461-0

  • Online ISBN: 978-3-7091-9292-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation